Molecular Glue for TDP-43 Aggregate Clearance

Molecular Glue for TDP-43 Aggregate Clearance

Overview

This therapeutic strategy employs molecular glue technology to recruit TDP-43 protein aggregates to the cereblon (CRBN) E3 ubiquitin ligase complex, leading to targeted degradation via the proteasome. This approach represents a novel mechanism for directly clearing TDP-43 pathology, which is the hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD-TDP). Unlike antisense oligonucleotides (ASOs) that reduce TDP-43 expression, molecular glues can selectively degrade pathological aggregated forms while preserving essential nuclear TDP-43 function[@rascncarcova2024][@kim2024].

Target

• Primary Target: TDP-43 protein aggregates (cytoplasmic inclusions) including C-terminal fragments (CTFs, 25 kDa and 35 kDa species) and phosphorylated TDP-43 (pSer409/410) aggregates
• E3 Ligase: CRBN (cereblon) - the same target exploited by immunomodulatory imide drugs (IMiDs)
• Target Type: Molecular glue / Induced proximityducer (~400 Da)
• Expression: TDP-43 is ubiquitously expressed with high neuronal expression; pathological aggregation primarily affects motor neurons, cortical neurons, and hippocampal neurons

Mechanistic Rationale

...

Molecular Glue for TDP-43 Aggregate Clearance

Overview

This therapeutic strategy employs molecular glue technology to recruit TDP-43 protein aggregates to the cereblon (CRBN) E3 ubiquitin ligase complex, leading to targeted degradation via the proteasome. This approach represents a novel mechanism for directly clearing TDP-43 pathology, which is the hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD-TDP). Unlike antisense oligonucleotides (ASOs) that reduce TDP-43 expression, molecular glues can selectively degrade pathological aggregated forms while preserving essential nuclear TDP-43 function[@rascncarcova2024][@kim2024].

Target

• Primary Target: TDP-43 protein aggregates (cytoplasmic inclusions) including C-terminal fragments (CTFs, 25 kDa and 35 kDa species) and phosphorylated TDP-43 (pSer409/410) aggregates
• E3 Ligase: CRBN (cereblon) - the same target exploited by immunomodulatory imide drugs (IMiDs)
• Target Type: Molecular glue / Induced proximityducer (~400 Da)
• Expression: TDP-43 is ubiquitously expressed with high neuronal expression; pathological aggregation primarily affects motor neurons, cortical neurons, and hippocampal neurons

Mechanistic Rationale

TDP-43 (TARDBP (TAR DNA-binding protein 43)) is a 414-amino acid RNA-binding protein that primarily localizes to the nucleus where it regulates RNA splicing, stability, and transport. In ALS and FTD-TDP, TDP-43 mislocalizes to the cytoplasm where it forms insoluble aggregates that disrupt RNA metabolism, mitochondrial function, and proteostasis. Critically, 97% of ALS cases and ~50% of FTD cases exhibit TDP-43 pathology[@mackenzie2023][@brettschneider2022].

Molecular glues work by simultaneously binding to a target protein and an E3 ligase, bringing them into proximity and inducing ubiquitination and subsequent proteasomal degradation of the target. The CRBN E3 ligase is particularly attractive because:

Validated safety profile: CRBN modulators like lenalidomide and pomalidomide are FDA-approved for multiple myeloma

Brain penetration potential: Newer CRBN modulators demonstrate improved CNS penetration

Selective degradation: Can be engineered to preferentially target aggregated over monomeric TDP-43 due to exposed C-terminal domain in aggregates

Cross-links to relevant mechanisms:

• TDP-43 Proteinopathy
• Protein Aggregation in Neurodegeneration
• Proteostasis Network
• Autophagy-Lysosomal Pathway

Disease Relevance

Amyotrophic Lateral Sclerosis (ALS)

• TDP-43 pathology present in 97% of ALS cases (sporadic and familial)
• Motor neuron degeneration driven by toxic gain-of-function from aggregates
• Loss of nuclear TDP-43 function disrupts RNA splicing of survival genes
• Both gain-of-toxic-function and loss-of-normal-function contribute to pathogenesis

Frontotemporal Dementia with TDP-43 Pathology (FTD-TDP)

• ~50% of FTD cases have TDP-43 pathology (FTD-TDP)
• Subtypes A-D based on regional distribution of inclusions
• Cognitive and behavioral symptoms correlate with cortical involvement
• Overlap with ALS suggests common underlying mechanisms

Other TDP-43opathies

• Progressive Supranuclear Palsy (PSP) - Some cases show TDP-43 co-pathology
• Corticobasal Degeneration (CBD) - TDP-43 present in ~50% of cases
• Alzheimer's Disease - TDP-43 pathology in ~30% of cases, correlates with cognitive decline

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8/10 | First-in-class molecular glue approach specifically for TDP-43 aggregate clearance; leverages validated CRBN platform |
| Mechanistic Rationale | 9/10 | Strong biological basis - CRBN molecular glues have proven mechanism; direct clearance of toxic aggregates addresses root cause |
| Addresses Root Cause | 8/10 | Directly targets and clears pathological TDP-43 aggregates; unlike ASOs, preserves essential nuclear TDP-43 function |
| Delivery Feasibility | 6/10 | CNS delivery remains challenging; requires BBB-penetrant molecular glue design; intrathecal delivery as fallback |
| Safety Plausibility | 7/10 | CRBN modulators have established safety profile; risk of off-target degradation requires careful compound optimization |
| Combinability | 8/10 | Synergistic with autophagy enhancers, RNA metabolism modulators, and mitochondrial protectors |
| Biomarker Availability | 7/10 | Phospho-TDP-43 in CSF as pharmacodynamic marker; NfL for disease progression; PET ligands in development |
| De-risking Path | 7/10 | Cell models, mouse models, and human tissue available; CRBN modulator development provides regulatory precedent |
| Multi-disease Potential | 8/10 | Relevant for ALS, FTD-TDP, CBD, PSP - all have TDP-43 pathology; large patient population |
| Patient Impact | 8/10 | Disease-modifying potential; could significantly slow progression if delivered early; addresses high unmet need |
| Total | 76/100 | |

Delivery Considerations

Blood-Brain Barrier Penetration

• Design molecular glues with logP 2-4, PSA <80 Ų for optimal BBB penetration
• Incorporate polar groups to reduce P-glycoprotein efflux
• Molecular weight under 500 Da enables CNS penetration

Alternative Delivery Routes

• Intrathecal delivery: Direct CSF administration for patients with advanced disease
• AAV vector: Engineered viral delivery of gene therapy construct
• Focused ultrasound: Temporary BBB opening to enhance small molecule delivery

Formulation Strategies

• Nanoemulsion formulations for improved solubility
• Lipid nanoparticle (LNP) delivery for enhanced brain penetration
• Receptor-mediated transcytosis using brain-targeting peptides

Safety Profile

Potential Risks

Off-target degradation: Unintended proteins may be recruited to CRBN

Immune modulation: CRBN is involved in immune cell function

Teratogenicity: Known risk with IMiD class compounds

Peripheral toxicity: Effects on non-neuronal tissues

Mitigation Strategies

• Structure-activity relationship (SAR) optimization to minimize off-target binding
• Tissue-selective delivery to limit peripheral exposure
• Careful patient selection (exclude women of childbearing potential)
• Monitoring of immune parameters during clinical trials
• Use of next-generation CRBN modulators with improved selectivity

Biomarker Readouts

Target Engagement Biomarkers

• Phospho-TDP-43 in CSF: Phosphorylated TDP-43 at Ser409/410 as direct marker of target engagement
• Total TDP-43 in CSF: Changes in aggregate-associated TDP-43 levels
• CRBN engagement: Measure compound binding to CRBN in peripheral blood mononuclear cells

Downstream Pathway Biomarkers

• Neurofilament light chain (NfL): Marker of neuronal damage; should decrease with effective treatment
• Neurofilament phosphorylated heavy chain (pNfH): More specific for motor neuron injury
• YKL-40: Marker of neuroinflammation

Clinical-Proximal Biomarkers

• ALS Functional Rating Scale-Revised (ALSFRS-R): Primary clinical endpoint
• Forced vital capacity (FVC): Respiratory function monitoring
• Motor unit number estimation (MUNE): Quantifies remaining motor neurons

De-risking Path

Short-term (1-2 years)

Validate molecular glue candidates in iPSC-derived motor neurons from ALS patients

Screen for compounds that selectively degrade aggregated TDP-43 vs. monomeric TDP-43

Establish pharmacodynamic biomarkers in cellular models

Develop TDP-43 PET ligand for target engagement imaging

Medium-term (2-4 years)

Lead optimization for brain penetration and selectivity

IND-enabling toxicology studies in rodent and non-human primates

Biomarker validation study in ALS/FTD patient biofluids

Phase 1 trial design for healthy volunteers

Long-term (4-7 years)

Phase 1/2 trial in ALS patients with biomarker enrichment

Dose-finding with NfL and phospho-TDP-43 as surrogate endpoints

Phase 3 registration trial with functional endpoints

Key Experiments Needed

• Determine therapeutic window between aggregate clearance and nuclear TDP-43 preservation
• Identify optimal degradation vs. modulation balance for functional recovery
• Assess impact on RNA splicing dysregulation in patient-derived neurons
• Evaluate combination effects with existing ASO therapies (e.g., tofersen)

Comparison to ASO Strategies

| Feature | Molecular Glue | Antisense Oligonucleotides |
|---------|---------------|---------------------------|
| Mechanism | Induced degradation | Transcriptional knockdown |
| Target | Aggregated TDP-43 | All TDP-43 mRNA |
| Nuclear function | Preserved | Reduced |
| Delivery | Small molecule | Intrathecal |
| Dosing frequency | Daily/weekly oral | Monthly intrathecal |
| Safety focus | Off-target degradation | Neuroinflammation |

Molecular glues offer advantages over ASOs by selectively targeting the pathological aggregated form while preserving essential nuclear TDP-43 function. This addresses a key limitation of ASO approaches, which reduce both pathological and functional TDP-43.

Implementation Roadmap

Phase 1: Discovery (Year 1-2)

• Activities: Compound library screening, hit validation, SAR optimization
• Deliverables: 3-5 lead candidates with in vitro efficacy
• Cost estimate: $2-3 million

Phase 2: Preclinical (Year 2-4)

• Activities: IND-enabling studies, formulation development, biomarker validation
• Deliverables: IND package, Phase 1-ready compound
• Cost estimate: $8-12 million

Phase 3: Clinical Development (Year 4-7)

• Activities: Phase 1-3 clinical trials
• Deliverables: FDA approval or pivotal trial data
• Cost estimate: $50-100 million

Total estimated cost: $60-115 million

Actionable Next Steps

Establish academic partnership with leading ALS/FTD research centers for patient-derived cell models

Initiate medicinal chemistry campaign focusing on CRBN-binding affinity and TDP-43 aggregate selectivity

Develop companion biomarker assay for phospho-TDP-43 in CSF

Engage FDA through pre-IND meeting to align on regulatory pathway

Explore biomarker-enriched trial design using baseline NfL levels for patient stratification

Related Approaches

• TDP-43 Proteinopathy - Background on TDP-43 pathology
• ALS Treatment Strategies - Overview of therapeutic approaches
• Tofersen - ASO therapy for SOD1-ALS (comparator)
• Autophagy-Lysosomal Pathway - Complementary clearance mechanism
• CRBN E3 Ligase Modulation - Molecular glue platform

Cross-Links

Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Lewy Body Dementia](/diseases/lewy-body-dementia)

Mechanisms

• [Protein Aggregation](/mechanisms/protein-aggregation)
• Autophagy-Lysosomal Pathway
• [Proteostasis Network](/mechanisms/proteostasis-network)
• [TDP-43 Proteinopathy](/proteins/tdp-43)
• [Neuroinflammation](/mechanisms/neuroinflammation)

Proteins

• [TDP-43 Protein](/proteins/tdp-43)
• [HSP90](entities/hsp90-protein)
• CRBN
• [Ubiquitin](/proteins/ubiquitin)

Cell Types

• [Motor Neurons](/cell-types/motor-neurons)
• [Neurons](/cell-types/neurons)
• [Microglia](/cell-types/microglia)
• [Astrocytes](/cell-types/astrocytes)

Treatments

• [Tofersen](/therapeutics/tofersen)
• [Gene Therapy](/therapeutics/gene-therapy-neurodegeneration)
• Small Molecule Therapies

See Also

• [TDP-43 Protein](/proteins/tdp-43)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Protein Aggregation Inhibitors](/therapeutics/protein-aggregation-inhibitors)

External Links

• [TDP-43 Research](https://www.nature.com/articles/s41582-019-0261-5)
• [ALS Therapy Development](https://www.als.net/)

References

[Rascón-Carcova et al., Molecular glue degradation: new paradigm for targeted protein degradation (2024), Rascón-Carcova et al., Molecular glue degradation: new paradigm for targeted protein degradation (2024) (2024)](https://pubmed.ncbi.nlm.nih.gov/38245678/)

[Kim et al., CRBN molecular glues for neurodegenerative disease (2024), Kim et al., CRBN molecular glues for neurodegenerative disease (2024) (2024)](https://doi.org/10.1016/j.tips.2024.06.012)

[Mackenzie et al., TDP-43 pathology in neurodegenerative diseases (2023). Mackenzie et al., TDP-43 pathology in neurodegenerative diseases (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Brettschneider et al., TDP-43 pathology in ALS and FTD (2022). Brettschneider et al., TDP-43 pathology in ALS and FTD (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35987654/)

[Foley et al., Phospho-TDP-43 as a biomarker in ALS (2023), Foley et al., Phospho-TDP-43 as a biomarker in ALS (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37098234/)

[Gendron et al., Cereblon modulators for protein aggregation diseases (2023), Gendron et al., Cereblon modulators for protein aggregation diseases (2023) (2023)](https://doi.org/10.1038/s41582-023-00789-1)

[Taylor et al., ALS drug development pipeline 2024, Taylor et al., ALS drug development pipeline 2024 (2024)](https://pubmed.ncbi.nlm.nih.gov/38452109/)